Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved..
Antibodies are important for vaccine efficacy. Targeting antigens to antigen-presenting cells (APCs) increases antibody levels. Here, we explore the role of antigen valency in MHC class II (MHCII)-targeted vaccines delivered as DNA. We design heterodimeric proteins that carry either two identical (bivalent vaccines), or two different antigens (monovalent vaccines). Bivalent vaccines with two identical influenza hemagglutinins (HA) elicit higher amounts of anti-HA antibodies in mice than monovalent versions with two different HAs. Bivalent vaccines increase the levels of germinal center (GC) B cells and long-lived plasma cells. Only HA-bivalent vaccines completely protect mice against challenge with homologous influenza virus. Similar results are obtained with other antigens by targeting CD11c and Xcr1 on dendritic cells (DCs) or when administering the vaccine as protein with adjuvant. Bivalency probably increases B cell responses by cross-linking BCRs in readily observable DC-B cell synapses. These results are important for generating potent APC-targeted vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Cell reports - 39(2022), 9 vom: 31. Mai, Seite 110901 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hinke, Daniëla Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.06.2022 Date Revised 06.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2022.110901 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341713597 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341713597 | ||
| 003 | DE-627 | ||
| 005 | 20231226204753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2022.110901 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341713597 | ||
| 035 | |a (NLM)35649357 | ||
| 035 | |a (PII)S2211-1247(22)00676-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hinke, Daniëla Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2022 | ||
| 500 | |a Date Revised 06.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Antibodies are important for vaccine efficacy. Targeting antigens to antigen-presenting cells (APCs) increases antibody levels. Here, we explore the role of antigen valency in MHC class II (MHCII)-targeted vaccines delivered as DNA. We design heterodimeric proteins that carry either two identical (bivalent vaccines), or two different antigens (monovalent vaccines). Bivalent vaccines with two identical influenza hemagglutinins (HA) elicit higher amounts of anti-HA antibodies in mice than monovalent versions with two different HAs. Bivalent vaccines increase the levels of germinal center (GC) B cells and long-lived plasma cells. Only HA-bivalent vaccines completely protect mice against challenge with homologous influenza virus. Similar results are obtained with other antigens by targeting CD11c and Xcr1 on dendritic cells (DCs) or when administering the vaccine as protein with adjuvant. Bivalency probably increases B cell responses by cross-linking BCRs in readily observable DC-B cell synapses. These results are important for generating potent APC-targeted vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a DC targeting | |
| 650 | 4 | |a DC-B cell synapse | |
| 650 | 4 | |a DNA vaccine | |
| 650 | 4 | |a T cell responses | |
| 650 | 4 | |a antibody responses | |
| 650 | 4 | |a antigen multivalency | |
| 650 | 4 | |a heterodimer | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a myeloma | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 650 | 7 | |a Hemagglutinins |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 650 | 7 | |a Vaccines, DNA |2 NLM | |
| 700 | 1 | |a Andersen, Tor Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Gopalakrishnan, Ramakrishna Prabhu |e verfasserin |4 aut | |
| 700 | 1 | |a Skullerud, Lise Madelene |e verfasserin |4 aut | |
| 700 | 1 | |a Werninghaus, Ina Charlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Grødeland, Gunnveig |e verfasserin |4 aut | |
| 700 | 1 | |a Fossum, Even |e verfasserin |4 aut | |
| 700 | 1 | |a Braathen, Ranveig |e verfasserin |4 aut | |
| 700 | 1 | |a Bogen, Bjarne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 39(2022), 9 vom: 31. Mai, Seite 110901 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:9 |g day:31 |g month:05 |g pages:110901 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2022.110901 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 9 |b 31 |c 05 |h 110901 | ||